The Beat Childhood Cancer Research Consortium is a group of 40+ universities and children's hospitals that offer a worldwide network of childhood cancer clinical trials coordinated by Levine Children’s Hospital.
Beat Childhood Cancer Research Consortium has a proven track record of managing multi-site clinical trials from start to finish. We have successfully opened nineteen Phase I and II trials for pediatric cancer patients including four Feasibility trials using Molecular Guided Therapy in children with relapsed cancers. Eleven Phase I/II trials have been completed to date and are published or in submission for publication.
Beat Childhood Cancer Research Consortium has successfully managed four FDA approved IND applications, two FDA approved IDE applications, as well as multiple FDA approved EIND applications. We have obtained Orphan Disease Designation as well as Breakthrough Therapy Designation for DFMO in Neuroblastoma. We are working diligently to move this drug to approval with our pharmaceutical partners.
|Giselle Sholler, MD||Chair, Beat Childhood Cancer|
|Patrick Lacey||Executive Advisor | Founder, Beat Nb|
|William Ferguson, MD||Cardinal Glennon Children’s Medical Center
Saint Louis University School of Medicine
|Jaqueline Kraveka, DO||Medical University of South Carolina|
|Genevieve Bergendahl, PNP, MSN, CCRP||Clinical Program Director, Beat Childhood Cancer|
|Javier Oesterheld, MD||Levine Children’s Hospital, Charlotte NC|